BioCentury
ARTICLE | Finance

Flexus redux

Why Flexus' VCs are back for seconds with cancer company FLX

May 2, 2016 7:00 AM UTC

Venture backers of Flexus Biosciences Inc. are back for round two with spinout FLX Bio Inc. This time, the goal is to develop the cancer company's assets much further before entertaining M&A offers.

Last week, FLX raised $50 million in a series B round from The Column Group, Topspin Partners, Kleiner Perkins Caufield & Byers and Celgene Corp. (NASDAQ:CELG). FLX also disclosed it had raised $29 million in an A round last May with TCG, KPCB and Celgene. ...